We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Akron Biotech has signed an exclusive global agreement with Switzerland-based Octapharma to produce virally inactivated Human AB Serum for the cell therapy market using the latter’s Octaplas.
Fresenius Kabi has decided to terminate the company’s previously announced merger agreement with Akorn, a United States-based manufacturer and marketer of prescription and over-the-counter pharmaceutical products.